Last $55.98 USD
Change Today +0.10 / 0.18%
Volume 1.5M
INSY On Other Exchanges
Symbol
Exchange
Frankfurt
As of 8:10 PM 03/3/15 All times are local (Market data is delayed by at least 15 minutes).

insys therapeutics inc (INSY) Snapshot

Open
$57.71
Previous Close
$55.88
Day High
$59.00
Day Low
$51.45
52 Week High
02/26/15 - $61.52
52 Week Low
05/15/14 - $20.52
Market Cap
2.0B
Average Volume 10 Days
542.4K
EPS TTM
$1.03
Shares Outstanding
35.5M
EX-Date
--
P/E TM
54.3x
Dividend
--
Dividend Yield
--
Current Stock Chart for INSYS THERAPEUTICS INC (INSY)

Related News

No related news articles were found.

insys therapeutics inc (INSY) Related Businessweek News

No Related Businessweek News Found

insys therapeutics inc (INSY) Details

Insys Therapeutics, Inc., a commercial-stage specialty pharmaceutical company, develops and commercializes supportive care products. It focuses on utilizing its proprietary formulation technologies to address the clinical shortcomings of existing commercial pharmaceutical products. The company markets Subsys, a proprietary sublingual fentanyl spray for breakthrough pain in opioid-tolerant cancer patients; and Dronabinol Oral Solution, a proprietary orally administered liquid formulation of dronabinol. It offers its Subsys through its incentive-based commercial sales force. The company also provides Dronabinol SG Capsule, a generic equivalent to Marinol (dronabinol), an approved second-line treatment for chemotherapy-induced nausea and vomiting, and anorexia associated with weight loss in patients with AIDS. Insys Therapeutics, Inc. was incorporated in 1990 and is headquartered in Chandler, Arizona.

202 Employees
Last Reported Date: 03/5/14
Founded in 1990

insys therapeutics inc (INSY) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $1.0M
Chief Financial Officer and Principal Account...
Total Annual Compensation: $337.9K
Consultant
Total Annual Compensation: $369.8K
Compensation as of Fiscal Year 2013.

insys therapeutics inc (INSY) Key Developments

Insys Therapeutics, Inc. Announces Unaudited Consolidated Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2014

INSYS Therapeutics, Inc. announced unaudited consolidated earnings results for the fourth quarter and full year ended December 31, 2014. For the quarter, net revenue of the company increased to $66.5 million versus $40.2 million in the fourth quarter of 2013. Income from operations was $16.1 million against $14.4 million and income before income taxes was $16.2 million against $14.4 million reported last year. Net income was $9.3 million or $0.25 per diluted share compared to net income of $24.1 million or $0.67 per diluted share per diluted share for the fourth quarter of 2013. Non-GAAP adjusted net income, which excludes the tax benefit and expense, was $19.5 million or $0.53 per diluted share versus $17.1 million or $0.47 per diluted share in the fourth quarter of 2013. Adjusted income before income taxes was $20.3 million against $16.6 million reported last year. EBITDA was $16.9 million against $14.9 million and adjusted EBITDA was $21.0 million against $17.1 million reported last year. Net revenue for the year ended December 31, 2014, was $222.1 million, an increase of $122.8 million as compared to $99.3 million for the year ended December 31, 2013. Income from operations was $64.0 million against $32.6 million and income before income taxes was $64.2 million against $31.6 million reported last year. Net income for 2014 was $38.0 million, or $1.10 per basic and $1.04 per diluted share, compared to net income of $40.4 million, or $1.56 per basic and $1.41 per diluted share, for 2013. Non-GAAP adjusted net income, which adjusts for non-cash stock compensation expense and non-cash income tax expense was $78.7 million, or $2.15 per diluted share, compared to $38.3 million, or $1.33 per diluted share, in the prior year. Adjusted income before income taxes was $79.5 million against $38.8 million reported last year. EBITDA was $66.5 million against $34.3 million and adjusted EBITDA was $81.8 million against $40.6 million reported last year.

Insys Therapeutics, Inc. Receives Fast Track Designation to its Pharmaceutical Cannabidiol Formulation from U.S. Food and Drug Administration

INSYS Therapeutics, Inc. announced that the U.S. Food and Drug Administration has granted Fast Track designation to its pharmaceutical cannabidiol (CBD) formulation for the treatment of Dravet syndrome, a rare form of childhood epilepsy. FDA's Fast Track program facilitates the development and review of drugs intended to treat serious conditions and address an unmet medical need. A drug development program with Fast Track designation is afforded greater access to the FDA for the purpose of expediting the drug's development, review and potential approval to get important new drugs to the patient earlier. The company expects that Insys' new, DEA-inspected facility in Round Rock, Texas will allow the company to manufacture ample quantities of CBD for its research and commercial plans. Cannabidiol (CBD) is one of at least 60 active cannabinoids identified in cannabis. CBD is considered to have a wider scope of medical applications than tetrahydrocannabinol (THC), and appears to have anti-convulsive action in animal models.

Insys Therapeutics In-Licenses Novel Mast Cell Therapy for Chronic Pelvic Pain

Insys Therapeutics, Inc. has entered into an exclusive sub-license agreement with Gold Coast Therapeutics to develop a unique combination of Cromolyn Sodium and Cetirizine as a new chemical entity for the treatment of chronic prostatitis/chronic pelvic pain syndrome, or CP/CPPS. Data from preclinical studies conducted at Northwestern University implicate mast cells as mediators of chronic pelvic pain associated with the prostate, and demonstrate that mast cell markers are elevated in men with CP/CPPS.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
INSY:US $55.98 USD +0.10

INSY Competitors

Market data is delayed at least 15 minutes.

Company Last Change
ARIAD Pharmaceuticals Inc $7.95 USD -0.08
Array BioPharma Inc $8.05 USD -0.15
BioDelivery Sciences International Inc $15.07 USD -0.25
Depomed Inc $22.99 USD -0.07
Spectrum Pharmaceuticals Inc $6.06 USD -0.10
View Industry Companies
 

Industry Analysis

INSY

Industry Average

Valuation INSY Industry Range
Price/Earnings 39.3x
Price/Sales 9.9x
Price/Book 13.4x
Price/Cash Flow 37.0x
TEV/Sales 9.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact INSYS THERAPEUTICS INC, please visit www.insysrx.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.